Expanded biotech company, 10x Genomics, moves forward, announces plans to acquire Scale Biosciences for further growth.
In a strategic move aimed at driving innovation forward, 10x Genomics, a leading company in the field of genomics, has announced the acquisition of Scale Biosciences. The deal, worth $30 million in cash and stock, was made based on the fundamentals of strategy and a shared vision.
Giovanna Prout, the CEO of Scale Biosciences, spent more than twelve years at Illumina before moving to a role at 10x Genomics for four years. Now, she returns to 10x Genomics as the CEO of Scale Biosciences, albeit with a different connection. Due to the deal, she had to separate her previous connection with 10x Genomics.
Serge Saxonov, CEO of 10x Genomics, sees the acquisition as a technology acquisition that will drive innovation forward. He is particularly excited about the integration of Scale's technology into the Chromium portfolio, which will deliver new capabilities.
Scale Biosciences' core products include QuantumScale Single Cell RNA Kits, ScalePlex, and a Single Cell Methylation Kit. Their technology is renowned for its split-pool combinatorial barcoding approach, which increases the scale and plex of single cell experiments.
Garry Nolan, co-founder of Scale Biosciences, shares Saxonov's excitement. He sees the acquisition as the next step in the evolution of the technology and believes that the possibility of bringing Scale's technology together with 10x Genomics' could be groundbreaking.
The acquisition comes at a time when Scale Biosciences is making significant strides in the single cell field. They have instigated large scale projects such as CZI's Billion Cell Project and the Arc Institute's Virtual Cell Atlas single cell initiative. Both 10x Genomics and Scale Biosciences were partners in CZI's Billion Cell Initiative.
Prout is proud of what Scale Biosciences built and is excited about the deal, citing 10x Genomics as a market leader with global market reach. She plans to watch and see how 10x Genomics will take the technology in the future.
The primary focus of the acquisition for 10x Genomics is to increase the scale of single cell experiments. The goal is to integrate Scale's technology into the Chromium portfolio to deliver new capabilities.
The acquisition offer was filed on September 8, 2025. The responsibility for Scale Biosciences was taken over by scPharmaceuticals Inc., which was acquired by Seacoast Merger Sub, a subsidiary of MannKind. Before the takeover, the CEO of scPharmaceuticals was not specified in the available search results.
Prout and Saxonov have had many productive interactions over the years. She is looking forward to continuing this productive relationship as they work together to push the boundaries of genomics.
In conclusion, the acquisition of Scale Biosciences by 10x Genomics is a significant step forward in the field of genomics. With the integration of Scale's technology into 10x Genomics' portfolio, we can expect to see new and exciting capabilities in single cell experiments.
